Tiny pumps patch in large molecules for drug delivery

Researchers at Purdue University have developed a new type of pump for drug-delivery patches that promises to deliver a wider range of medication than is now possible through conventional patches.

"We have developed a simple pump that's activated by touch from the heat of your finger and requires no battery," says Babak Ziaie, a Purdue professor of electrical and computer engineering and biomedical engineering. The pump contains a liquid that boils at body temperature so that the heat from a finger's touch causes it to rapidly turn to a vapor, exerting enough pressure to force drugs through microneedles on the patches.

This opens up the world of drug-delivery patches to larger molecules that cannot be absorbed through the skin on transdermal patches.

Ziaie envisions throw-away patches containing 20-micron-diameter needles that would act as a bandage. "You would use it and discard," he says.

Research findings are detailed in a paper being presented during the 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences on Oct. 3-7 at University of Groningen in the Netherlands.

- check out Purdue's press release

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

ApiJect systems snared a $590 million from the U.S. government to build a multi-facility campus to crank out more than 3 billion injectors per year.

A team at the University of New South Wales Sydney developed a light-activated liposome that could deliver CRISPR treatments with fewer side effects.